ImmunOs Therapeutics AG, a spin-off of the University of Zurich and University of Basel, is leading the discovery and development of the next generation of novel human immunomodulatory proteins for cancer treatment that not only have direct anti-tumor effects but also remodel the tumor microenvironment and enhance the efficacy of existing immunotherapies. The team has extensive expertise in the field of drug development and global commercialization in immunotherapy, immunology, and oncology.
ImmunOs’ lead clinical candidate is a single multitasking protein agent, for treating solid tumors. The next generation, novel platform of multitasking biologics targets diverse immunoregulatory receptors that activate anti-tumor responses and is built upon years of research and development. ImmunOs Proteins work directly on the Innate Immune System (MDSCs, Macrophages, NK Cells and Neutrophils) and Indirectly on the Adaptive Immune System by allowing the expansion of T cells, leading to strong anti-tumor responses as monotherapy and in combination with checkpoint inhibitors (PD-1, CTLA-4, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancer indications.
UZH Life Sciences Fund and Schroder Adveq will join the current group of investors. In December 2017, Immunos Therapeutics has announced the closing of a 2.3 Million CHF financing round.
(Press release / SK)